In this issue:
Elotuzumab for relapsed/refractory MM
Targeting CD38 with daratumumab monotherapy in MM
Melphalan, prednisone with thalidomide or lenalidomide in untreated MM
VTD ± cyclophosphamide in untreated MM
Silent VTE in MM treated with lenalidomide
Revised ISS for MM
Lenalidomide and vorinostat maintenance post-SCT in MM
Salvage infusional chemotherapy regimens for recurrent/refractory MM
Bendamustine, bortezomib and prednisone for newly diagnosed MM
Four genes predict progression from smouldering to symptomatic MM
Please login below to download this issue (PDF)